- Home
- Companies
- united kingdom
- whole blood samples
Show results for
Refine by
Whole Blood Samples Suppliers In United Kingdom
5 companies found
based inStow-cum-Quy, UNITED KINGDOM
We are a product engineering development company based in Cambridge, UK. Originally founded in 2002 by Andrew Ede and Danny Godfrey (the E and the G of eg technology), the company has grown organically and profitably and is now a thriving company ...
We worked with Sphere Medical throughout the development of the product, first designing a research version, followed by the CE-approved Pelorus 1000 and, most recently, the IVD CE-approved Pelorus ...
based inOxford, UNITED KINGDOM
Founded in 2012, we are the leading pharmatech company and the first to automate drug discovery. As a full stack AI drug discovery company, we generate our own data before combining the analytical power of AI with the creativity and expertise of our ...
EXS21546 is our peripherally-restricted and selective antagonist of the Adenosine A2a Receptor. It is designed for anti-cancer immunotherapy, combatting adenosine related immunosuppressive effects, through T-cell ...
based inUpton-Upon-Severn, UNITED KINGDOM
Established in 1979, Bio-Diagnostics is privately owned, rapidly growing, UK bio-tech business, based 40 miles south west of Birmingham, UK. Bio-Diagnostics is highly regarded and trusted globally, working closely with partners providing, ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune ...
based inDaresbury, UNITED KINGDOM
Point of Care (PoC) medical diagnostics is a $ multi-billion global market. Driven by patient need for self monitoring and healthcare cost savings, hand-held devices or readers offering rapid diagnostic test results are fast replacing often slow and ...
Patented technology currently in commercial development with a global haematology ...